Evidence map›Paper›PMID 28069569›Full record

ArticleCancer discovery2017

The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma.

Jiyuan Zhang, Sofija Vlasevska, Victoria A Wells, Sarah Nataraj, Antony B Holmes, Romain Duval, Stefanie N Meyer, Tongwei Mo, Katia Basso, Paul K Brindle and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers.

0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed
18.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

148 citing papers in PubMed, 238 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

88 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Jiyuan ZhangInstitute for Cancer Genetics, Columbia University, New York, New York.
Sofija VlasevskaInstitute for Cancer Genetics, Columbia University, New York, New York.
Victoria A WellsInstitute for Cancer Genetics, Columbia University, New York, New York.
Sarah NatarajInstitute for Cancer Genetics, Columbia University, New York, New York.
Antony B HolmesInstitute for Cancer Genetics, Columbia University, New York, New York.
Romain DuvalInstitute for Cancer Genetics, Columbia University, New York, New York.
Stefanie N MeyerInstitute for Cancer Genetics, Columbia University, New York, New York.
Tongwei MoInstitute for Cancer Genetics, Columbia University, New York, New York.
Katia BassoInstitute for Cancer Genetics, Columbia University, New York, New York.
Paul K BrindleDepartment of Biochemistry, St. Jude Children's Research Hospital, Memphis, Tennessee.
Shafinaz HusseinDepartment of Pathology and Laboratory Medicine, NorthWell Health, Staten Island University Hospital, Staten Island, New York.
Riccardo Dalla-FaveraInstitute for Cancer Genetics, Columbia University, New York, New York.
Laura PasqualucciInstitute for Cancer Genetics, Columbia University, New York, New York. lp171@cumc.columbia.edu.
Cancer Genetics (United States) · USColumbia University Irving Medical Center · USStaten Island University Hospital · USSt. Jude Children's Research Hospital · US

Funding

Translating Stress Response Targeted Therapy for B-Cell LymphomasP50CA192937 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ZELENETZ, ANDREW D. · 2016 to 2020
$10.9M
From pathogenesis to new therapeutic targets in Diffuse Large B cell LymphomaR35CA210105 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Riccardo Dalla-Favera · 2016 to 2026
$10.0M
Role of MLL2 Gene Inactivation in B cell Non Hodgkin LymphomaR01CA172492 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PASQUALUCCI, LAURA · 2013 to 2022
$3.6M
Role of acetyltransferase gene inactivation in follicular lymphoma pathogenesisR01CA164152 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DALLA-FAVERA, RICCARDO · 2012 to 2016
$1.6M
The coding genome of HIV-associated plasmablastic lymphomas in South AfricaR21CA192854 · NCI · WITS HEALTH CONSORTIUM (PTY), LTD · PI PASQUALUCCI, LAURA, RABADAN, RAUL · 2015 to 2016
$385k
NCI NIH HHS P50 CA192937NCI NIH HHS R01 CA164152NCI NIH HHS R01 CA172492NCI NIH HHS R21 CA192854NCI NIH HHS R35 CA210105
6 · The paper itself

Abstract

Inactivating mutations of the CREBBP acetyltransferase are highly frequent in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), the two most common germinal center (GC)-derived cancers. However, the role of CREBBP inactivation in lymphomagenesis remains unclear. Here, we show that CREBBP regulates enhancer/super-enhancer networks with central roles in GC/post-GC cell fate decisions, including genes involved in signal transduction by the B-cell receptor and CD40 receptor, transcriptional control of GC and plasma cell development, and antigen presentation. Consistently,

Indexed as

Genes, Tumor SuppressorAnimalsB-LymphocytesCell DifferentiationChromatinCREB-Binding ProteinEnhancer Elements, GeneticEpigenesis, GeneticGene Expression Regulation, NeoplasticGerminal CenterHaploinsufficiencyHumansLymphoma, FollicularLymphoma, Large B-Cell, DiffuseMice, Inbred C57BLMice, KnockoutBCL6 protein, humanChromatinCREB-Binding ProteinCREBBP protein, humanCrebbp protein, mouseProto-Oncogene Proteins c-bcl-6

Identifiers

PMID28069569
PMCPMC5386396
OpenAlexW2569993732

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.